eae! will take ont sale next ine sd} - Nd VIN apr on vi mach Bie“ey1;‘he& ei al 1 ithe’ ie ‘A2ini saleng ai ie an . “aesgucti “UL apy clon ms 13 hal hie. OF WOMEN’S HEALTH A Personalized 'd Approach To Treating Breast Cancer (NAPSA)—Diagnostic testing to determine the use of targeted therapy is a valuable tool in help- ing physicians guide treatment options for patients, particularly women who have been diagnosed with breast cancer. These diagnostic tests are designed to analyze the unique biology of a patient’s breast cancer to help doctors cus- tomize therapy. The goal is to maximize the effectiveness of appropriate drug treatments and to minimize their side effects. This “personalized” approach to testing is the future of medicine. Breast cancer tumors that are positive for certain hormone receptors may benefit from hor- monal therapy. HER2 status can tell how aggressive a breast cancer may be. HER2 genes are con- tained in the DNAofall normal breast cells and help breast cells grow. About 20 percent of breast cancers contain an abnormal number of HER2 genes or high concentration of HER2 protein in the cells. An abnormal amount or high concentration of HER2 is associated with cancer that is ageressive and therefore requires special treatment. Breast tissue can be tested for the presence of this protein or gene and routine testing is recom- mended for most women with breast cancer because the results may affect treatment recommen- dations and decisions. The HER2 test can determineif a patient has an abnormally high number of HER2 genes or proteins in the tumor tissue which would in turn support targeted treatment with the drugs which target HER2. New Testing Guidelines The American Society of Clinical Oncology (ASCO) and the Col- lege of American Pathologists Many believe the “personalized” approach to cancer testing is the future of medicine. (CAP) issued new HER2 testing practice guidelines earlier this year to help physicians have more accurate measurements of HER2 in breast cancer. In releasing the new guidelines, ASCO and CAP announced that approximately 20 percent of current HER2 testing may be inaccurate. Nowit is recommended that laboratories that perform HER2 testing be accredited to do this very important test. Given the importance of accurate testing, Dr. Bruce Horten, a national medical director for Genzyme Genetics, encourages women to talk to their doctors and request that their HER2 tests be sent to a laboratory that meets the ASCO and CAP HER2testing practice guidelines. Genzyme Genetics, based in Westborough, Mass., with labora- tory facilities across the U.S., is one of the first laboratories to implement these guidelines for HER2 breast cancer testing. Gen- zyme Genetics is a national leader in high-quality breast cancer predictive and prognostic analysis and receives nearly 20 percent of all newly diagnosed breast cancer cases in the U.S. for ancillary test- ing, including HER2 analysis. To learn more, visit www. genzymegenetics.com.
